Disease · HP_0001259

Coma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Coma. Diseases, record HP_0001259. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001259

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Coma
Open Targets ID: HP_0001259
Other names: Persistent vegetative state, Stupor, Unconsciousness
Highest stage of its drugs: Phase 3, for 1 of its 13 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HALOPERIDOL	CHEMBL54	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AMANTADINE	CHEMBL660	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BACLOFEN	CHEMBL701	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPHENIDATE	CHEMBL796	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LACOSAMIDE	CHEMBL58323	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MIDAZOLAM	CHEMBL655	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02486211	Amantadine to Speed Awakening After Cardiac Arrest	Phase 2	14	2019-12-04	Coma, Heart Arrest, Anoxia	AMANTADINE	Its record names the disease	ClinicalTrials.gov
NCT03814356	Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness	Phase 1	10	2025-10-29	Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury	METHYLPHENIDATE	Its record names the disease	ClinicalTrials.gov
NCT06549426	Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)	Not applicable	150		Coma, Electrographic Status Epilepticus	DIAZEPAM, KETAMINE, LACOSAMIDE, LEVETIRACETAM, LORAZEPAM, MIDAZOLAM, PROPOFOL, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03628391	Haloperidol for Delirium in Adult Critically Ill Patients	Phase 3	142		Delirium, Critical Illness, Intensive Care Psychosis, Cognitive Impairment, Cognitive Decline	HALOPERIDOL	Its record names the disease	ClinicalTrials.gov
NCT03443037	Benefits of Amantadine in Patients With Coma State		56		Coma; Prolonged, Amantadine	AMANTADINE	Its record names the disease	ClinicalTrials.gov
NCT02566720	Amantadine and Functional Improvement Following ABI Measured by MRI Tractography; A Pilot Study	Not applicable	10		Acquired Brain Injury, Coma, Persistent Vegetative State, Minimally Conscious State, Traumatic Brain Injury	AMANTADINE	Its record names the disease	ClinicalTrials.gov
NCT00221689	Intrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients	Phase 2	4		Traumatic Brain Injury, Cerebral Anoxia, Coma, Hypertonia, Dysautonomia	BACLOFEN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Amantadine vs Placebo: Nausea or Vomiting	0 of 7	0 of 7	14	NCT02486211	Trial comparisons
Amantadine vs Placebo: Rate of Awakening (Number of Patients Who Are Able to Follow Commands)	2 of 7	2 of 7	14	NCT02486211	Trial comparisons
Amantadine vs Placebo: Number of Participants With Severe or Intracranial Bleeding	0 of 7	0 of 7	14	NCT02486211	Trial comparisons
Amantadine vs Placebo: Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)	0 of 7	2 of 7	14	NCT02486211	Trial comparisons
Amantadine vs Placebo: deaths from any cause	4 of 7	3 of 7	14	NCT02486211	Trial comparisons
Amantadine vs Placebo: serious adverse events	0 of 7	0 of 7	14	NCT02486211	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37904241	DERIVED	1	PubMed
32967873	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001259

GET https://conductscience.org/api/diseases/v1/HP_0001259/targets?page=2

API reference For AI assistants